<?xml version="1.0" encoding="UTF-8"?>
<p id="par0090">In conclusion, the robust two-tier drug compound screening system established in this study represented a novel platform for conducting drug discovery programmes for COVID-19. The topical and/or systemic effects of cetilistat, diiodohydroxylquinoline, abiraterone acetate, and bexarotene should be further evaluated in suitable 
 <italic>ex vivo</italic> human organ culture or organoids, animal models, and/or clinical trials.
</p>
